 MENLO PARK, Calif. and BOSTON, May 17, 2021 GLOBE NEWSWIRE -- Adicet Bio, Inc. Nasdaq: ACET, a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the first quarter ended March 31, 2021. 